Article Details

Safety Outcomes When “Switching” Between Biosimilars and Reference Products | FDA

Retrieved on: 2023-12-05 22:20:59

Tags for this article:

Click the tags to see associated articles and topics

Safety Outcomes When “Switching” Between Biosimilars and Reference Products | FDA. View article details on hiswai:

Excerpt

They are a diverse category of products that include vaccines, proteins (such as insulins, monoclonal antibodies, and growth factors), as well as ...

Article found on: www.fda.gov

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo